0001193125-26-192508
SEC filingRevenue grew 7.6% to $828.8 million driven by bed additions and service demand, but net income declined 51.0% to $4.1 million due to legal settlements and higher depreciation from facility expansions, yielding negative free cash flow amid elevated capex.
Acadia Healthcare delivered revenue growth of 7.6% to $828.8 million in Q1 2026 from $770.5 million in the prior year, reflecting the impact of adding beds to existing facilities and sustained demand for behavioral health services. This aligns with management's commentary on same facility patient day growth resulting from capacity expansions and service needs, consistent with patterns observed in 2025. The company remains committed to providing high-quality, cost-effective care while pursuing business growth and long-term stockholder value.
Cash flow dynamics showed resilience in operations but strain from growth investments. Net cash provided by operating activities rose sharply to $61.5 million from $11.5 million, bolstered by stronger insurance reimbursements and state funding flows. However, capital expenditures totaled $76.6 million—down from $174.6 million prior year but still expansion-focused to boost facility capacity—resulting in negative free cash flow of $15.0 million. Management defines such capex as enhancing revenue potential, underscoring its strategic role during periods of significant expansion. Same facility metrics remain useful for isolating organic performance amid these dynamics.
Looking ahead, regulatory changes like the OBBBA's elimination of ACA subsidies and end to automatic renewals have driven ACA plan cost increases, though Acadia anticipates no material operational impact due to exemptions for its patient populations with chronic substance use disorders and complex medical conditions. Future legislative or judicial developments remain unpredictable, but the company's facility-focused strategy positions it to navigate evolving reimbursement landscapes while expanding access to care.